However, in the other (PD37495), clinical screening only detected LOH across RB1, the alternative allele being disrupted by balanced translocations with chromosomes 16 and 18 which were only detected by WGS, thus presenting the possibility that the proportion of MYCN amplified Rb tumours perceived to be RB1 wild type or have monoallelic RB1 loss maybe smaller than previously thought due to undetected RB1 mutations involving structural rearrangements. This evidence concerns the gene MYCN and neoplasm.